Aviceda Therapeutics: The company raised $64 million of venture funding from undisclosed investors on March 28, 2022. The company is an operator of a biotech business intended to develop breakthrough glycol-therapeutics.
Dren Bio: The company raised $62.5 million of venture funding from undisclosed investors on March 28, 2022. The company is a developer of a biotechnology platform intended to develop protein-based technologies to deplete pathogenic cells and agents in numerous diseases.
Incyclix Bio: The company raised Series B venture funding in a deal led by Boxer Capital on March 31, 2022. RA Capital Management and Eshelman Ventures also participated in the round. The company is a developer of small molecule inhibitors of cyclin-dependent kinases (CDKs) intended to provide treatment for patients with advanced and resistant cancers.
RNAimmune: The company raised $27 million of Series A funding led by Sirnaomics and Smooth River on March 29, 2022. Rotating Boulder Fund also participated in the round. The company is a provider of mRNA(messenger ribonucleic acid)-based therapeutics and vaccines intended to tackle indications in cancer, infectious and rare diseases.
VivoSense: The company raised $25 million of Series A venture funding in a deal led by Perceptive Advisors and Debiopharm Innovation Fund on March 30, 2022. Other undisclosed investors also participated in this round . The company is a developer of wearable biosensors and a healthcare analytics software designed to optimize data quality and results.
Diality: The company raised $25 million of of Series B2 venture funding from undisclosed investors on March 31, 2022. The company is a developer of a hemodialysis machine designed to improve the care and lives of patients with kidney disease.
Elucida Oncology: The company raised $22.3 million of venture funding in the form of conveertible debt from undisclosed investors on Mrach 28, 2022. The company is a developer of therapeutics designed to target cancer with precision engineering technology.
Osel: The company raised an estimated $20 million of venture funding from undisclosed investors on March 30, 2022. The company is a developer of live biotherapeutic products intended to harness the microbiome to improve health.
Cairdac: The company raised EUR 17 million of Series A venture funding in a deal led by Mérieux Equity Partners, Bpifrance and Supernova Invest on March 31, 2022. Sham Innovation Santé and Catp Expansion also participated in the round. The company is a developer of a leadless pacemaker incorporating a self-sustaining power technology that harvests the heart’s kinetic energy.
Homethrive: The company raised $16.5 million of Series B venture funding from undisclosed investors on March 28, 2022, putting the company’s pre-money valuation at $58.5 million. The company is a provider of care management and personal assistance services intended to help older adults live at home.
PocketHealth: The company raised CAD 20 million of Series A venture funding led by Questa Capital on March 31, 2022. Radical Ventures also participated in this round. The company is a developer of a secure online platform designed to receive and share sensitive medical imaging information.
Altoida: The company raised $4 million of Series A venture funding in a deal co-led by M Ventures and Whitecap Venture Partners on March 30, 2022. HonorHealth, Eisai Innovation, Alpana Ventures, Hikma Ventures, VI Partners, Fyrfly Venture Partners, and BTOV partners also participated in the round. The company is a developer of a medical diagnostic application designed to detect Alzheimer’s and dementia prior to its onset using augmented reality.
Spectrum Antimicrobials: The company raised $7.7 million of Series A venture funding from undisclosed investors on March 31, 2022. The company is an operator of a biotechnology firm focused on the control, prevention, and treatment of infectious diseases.
Virgo: The company raised $3.9 million in venture funding from undisclosed investors on March 29, 2022. The company is a developer of cloud-based software designed to accelerate results in GI clinical trials.
WEconnect Health Management: The company raised $3 million of Venture Funding from Fred Luddy and other undisclosed investors on March 31, 2022. The company is a developer of a rehabilitation progress tracking application designed to assist inpatient and outpatient healthcare systems, and sober living programs.
Jaguar Gene Therapy: The company is in the process of raising an undisclosed amount of venture funding from Samsung Life Insurance and T1D Fund on March 29, 2022. The company is an operator of a gene therapy discovery business intended to improve the quality of life of patients with severe genetic diseases.
